drugset / Trial / NCT06794541
A Study to Evaluate the Safety and Tolerability of Eravacycline in Pediatric Patients Aged 8 to 17 With Complicated Intra-abdominal Infections (cIAI)
Phase 2
Recruiting
35 enrolled
Tetraphase Pharmaceuticals, Inc
Innoviva Specialty Therapeutics · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
A Phase 2 trial to assess safety, tolerability, and pharmacokinetics of eravacycline in pediatric patients aged 8 to \<18 years with cIAI.
Timeline
- Start
- 2025-05-22
- Primary completion
- 2029-02-17
- Completion
- 2029-03-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eravacycline | Small molecule | 1.5 mg/kg | Intravenous |
| Subject | Eravacycline | Small molecule | 2 mg/kg | Intravenous |
Indications
No indication recorded.